Please assess the completion status of the following clinical trial:

Trial Title: Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. El Escorial criteria for definite or probable ALS~2. Either men or non pregnant women between 20-75 years of age.~3. Patient is mentally intact and psychologically stable~4. For early stage ALS- Patients will be with ALS-FRS-R scale of at least 30 and disease duration of less than 2 years.Or, for progressive stage ALS- Patients will be with an ALS-FRS-R scale of 15-30 and disease duration of less than 2 years~5. For early stage ALS- Patient has sufficiently bulky muscles. Or, for progressive stage ALS- Patient with at least 60% FVC~6. Participant understands the nature of the procedure and provides written informed consent prior to any study procedure.~Exclusion Criteria:~1. Positive test for HBV, HCV, HIV and Mycoplasma.~2. High protein in the CSF.~3. Lymphocytosis in the CSF.~4. Positive for anti-GM1 antibodies.~5. Patient has significant conduction blocks or slow nerve conduction velocities (a reduction of more than 30%) confirmed by nerve conduction velocity - EMG studies.~6. The patient is a respiratory dependent.~7. Renal failure, impaired hepatic function~8. Patients suffering from significant cardiac disease, malignant diseases or any other disease that may risk the patient or interfere with the ability to interpret the results~9. Active infections.~10. Participation in another clinical trial within 1 month prior to start of this study.~11. Subject unwilling or unable to comply with the requirements of the protocol.~12. Patient has not been treated previously with any cellular therapy.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MSC-NTF cells IM (Type: EXPERIMENTAL): Intramuscular administration in early stage patients
- MSC-NTF cells IT (Type: EXPERIMENTAL): Intrathecal administration in progressive stage patients

Based on this trial design, predict the completion outcome and termination type (if applicable).